Sagimet Biosciences Inc.

Contributing Author

Recent Articles by Sagimet Biosciences Inc.

Nov-13	Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire
Nov-10	Sagimet Biosciences Presents Two Denifanstat Posters at AASLD-The Liver Meeting 2025 SGMT GlobeNewswire
Oct-24	Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference SGMT GlobeNewswire
Oct-14	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences SGMT GlobeNewswire
Oct-07	Sagimet Biosciences Announces Upcoming Presentation at AASLD-The Liver Meeting 2025 SGMT GlobeNewswire
Oct-01	Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination SGMT GlobeNewswire
Sep-24	Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week SGMT GlobeNewswire
Sep-17	Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis SGMT GlobeNewswire
Sep-10	Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit SGMT GlobeNewswire
Aug-26	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences SGMT GlobeNewswire
Aug-13	Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire
Aug-05	Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference SGMT GlobeNewswire
Jun-09	Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025 SGMT GlobeNewswire
Jun-04	Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis SGMT GlobeNewswire
May-22	Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025 SGMT GlobeNewswire
May-08	Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates SGMT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.